Galera Therapeutics Inc (GRTX) Institutional Buying & Selling Tracker (Q2 2026)

Galera Therapeutics (GRTX) completed its merger into Obsidian Therapeutics on August 3, 2026. Shareholders of record as of July 31, 2026 will receive two types of contingent value rights (CVRs) for each share of Galera common stock they held: one entitling them to a pro-rata share of 80% of any future net proceeds from the Legacy Product over five years, and another for 95% of proceeds from the Supportive-Care Product Divestiture over ten years. These CVRs are contractual rights only, not tradable except in limited cases, and there is no guarantee any payments will be made. After the merger, former Galera shareholders hold only about 1.2% of the combined company's shares on a fully diluted basis, while Legacy Obsidian holders own ~51.6% and PIPE investors ~47.2%.

Galera Therapeutics closed its previously disclosed concurrent PIPE financing on July 31, 2026, selling shares of Series C non-voting convertible preferred stock for roughly $350 million in gross proceeds. The sale was done as a private placement exempt from registration under Section 4(a)(2) of the Securities Act, so it wasn't a public offering. The provided excerpt only covers Item 3.02 of the 8-K; the filing also lists Items 7.01 and 9.01, but those sections aren't included here.

Galera Therapeutics filed an 8-K disclosing a material modification to the rights of its security holders. The details are referenced under Item 5.03 of the filing, which is not included in this excerpt.

No AI summary for this filing type